Abstract
BACKGROUND The criteria used to allocate scarce COVID-19 vaccines are hotly contested. While some are pushing just to get vaccines into arms as quickly as possible, others advocate prioritization in terms of risk.
OBJECTIVE Our aim is to use demographic models to show the enormous potential of vaccine risk-prioritization in saving lives.
METHODS We develop a simple mathematical model that accounts for the age distribution of the population and of COVID-19 mortality. This model considers only the direct live-savings for those who receive the vaccine, and does not account for possible indirect effects of vaccination. We apply this model to the United States, Japan, and Bangladesh.
RESULTS In the United States, we find age-prioritization would reduce deaths during a vaccine campaign by about 93 percent relative to no vaccine and 85 percent relative to age-neutral vaccine distribution. In countries with younger age structures, such as Bangladesh, the benefits of age-prioritization are even greater.
CONTRIBUTION For policy makers, our findings give additional support to risk-prioritized allocation of COVID-19 vaccines. For demographers, our results show how the age-structures of the population and of disease mortality combine into an expression of risk concentration that shows the benefits of prioritized allocation. This measure can also be used to study the effects of prioritizing other dimensions of risk such as underlying health conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JRG and AM are supported by the Berkeley Population Center (NIH/National Institute of Child Health and Human Development [NICHD] program project P2CHD073964), the Center for the Economics and Demography of Aging (NIH/National Institute on Aging [NIA] grant 5P30AG012839), and Berkeley Formal Demography Workshops (NIH/NICHD grant R25HD08313). J.R.G. is also supported by NIH/NIA grant R01AG058940.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Publicly available data. U.S. age distribution from Human Mortality Database (www.mortality.org) Covid age-specific mortality from Goldstein and Lee (2020)
